“Patients,Trauma Survivors,Sweethearts,or Troublemakers?”: A Discourse Analysis of General Practitioners’ and Pharmacists’ Accounts of Clients on Opioid Substitution Treatment

Abstract

Despite the high level of scientific support for the effectiveness of opioid substitution treatments (OSTs), individuals who rely on this treatment are a highly stigmatized population within healthcare settings. Previous studies mainly focused on the experiences of OST clients, while the perspective of medical professionals regarding OST remains largely unexplored. This study aims to investigate the discourse of pharmacists and general practitioners about OST through the lens of positioning theory. To explore their stance toward OST, semi-structured interviews were conducted with 30 pharmacists and general practitioners working in pharmacies, community health centers, private medical practices, prisons, and drug treatment services in Flanders, Belgium. The participants of this study discursively constructed four storylines to position themselves and OST clients, namely, a biomedical, psychodynamic, biopsychosocial, and moralizing storyline. These storylines are based on historical explanatory addiction models, and their use varies according to the participant’s work setting. While the moralizing storyline was characterized by othering, stereotyping, and labeling, participants who applied the biopsychosocial storyline approached clients in a destigmatizing manner. To conclude, participants used the identified storylines to define the position of clients in OST, along with their related rights and duties. The dominant storyline thus shapes the view on and treatment of OST clients in a medical setting.

Keywords

stigma interviews opioid substitution treatment Belgium discourse analysis pharmacists general practitioners positioning theory

Get full access to this article

View all access options for this article.

References

Alves

P. C. G.

Stevenson

F. A.

Mylan

Pires

Winstock

Ford

(2021). How do people who use drugs experience treatment? A qualitative analysis of views about opioid substitution treatment in primary care (iCARE study). BMJ Open, 11(2), Article e042865. https://doi.org/10.1136/bmjopen-2020-042865

Andraka-Christou

Randall-Kosich

Totaram

(2021). Designing an “ideal” substance use disorder treatment center: Perspectives of people who have utilized medications for opioid use disorder. Qualitative Health Research, 31(3), 512–522. https://doi.org/10.1177/1049732320971231

Azbel

Bromberg

D. J.

Dvoryak

Altice

F. L.

(2022). Addiction treatment as prison governance: A critical discourse analysis of methadone delivery in Kyrgyz prisons. Contemporary Drug Problems, 49(1), 106–120. https://doi.org/10.1177/00914509211060723

Barnett

A. I.

Hall

Fry

C. L.

Dilkes-Frayne

Carter

(2018). Drug and alcohol treatment providers’ views about the disease model of addiction and its impact on clinical practice: A systematic review. Drug and Alcohol Review, 37(6), 697–720. https://doi.org/10.1111/dar.12632

Becoña

(2018). Brain disease or biopsychosocial model in addiction? Remembering the Vietnam Veteran Study. Psicothema, 30(3), 270–275. https://doi.org/10.7334/psicothema2017.303

Blomme

Makola

De Pau

Lambrechts

M.-C.

(2021). EVADRUG: An evaluation of the Belgian Drug Policy. B. S. P. Office. https://www.belspo.be/belspo/fedra/DR/DR83_EVADRUG_FinRep.pdf

Boksán

Dechant

Weiss

Hellwig

Stemmler

(2023). A meta-analysis on the effects of incarceration-based opioid substitution treatment. Medicine, Science & the Law, 63(1), 53–60. https://doi.org/10.1177/00258024221118971

Carl

Pasman

Broman

M. J.

Lister

J. J.

Agius

Resko

S. M.

(2023). Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug and Alcohol Dependence Reports, 6(9), Article 100138. https://doi.org/10.1016/j.dadr.2023.100138

Cavaiola

A. A.

(2020). Introduction to addiction theory. In Cavaiola

A. A.

Smith

(Eds.), A comprehensive guide to addiction theory and counseling techniques (1st ed., pp. 1–14). Routledge. https://doi.org/10.4324/9780429286933

10.

Cazalis

Lambert

Auriacombe

(2023). Stigmatization of people with addiction by health professionals: Current knowledge. A scoping review. Drug and Alcohol Dependence Reports, 9(4), Article 100196. https://doi.org/10.1016/j.dadr.2023.100196

11.

Cheetham

Picco

Barnett

Lubman

D. I.

Nielsen

(2022). The impact of stigma on people with opioid use disorder, opioid treatment, and policy. Substance Abuse and Rehabilitation, 13, 1–12. https://doi.org/10.2147/SAR.S304566

12.

Davies

Harré

(1990). Positioning: The discursive production of selves. Journal for the Theory of Social Behaviour, 20(1), 43–63. https://doi.org/10.1111/j.1468-5914.1990.tb00174.x

13.

De Bonte

Vander Laenen

(2022). Ervaringen met intra-group stigma: onderzoek bij cliënten van een opiaatsubstitutiebehandeling [Experiences with intra-group stigma: research among clients of an opioid substitution treatment]. Verslaving & Herstel, 2(3), 8.

14.

De Maeyer

Vanderplasschen

(2020). Substitution treatment for opiate-dependent persons. In Maggino

(Ed.), Encyclopedia of quality of life and well-being research (pp. 1–8). Springer International Publishing. https://doi.org/10.1007/978-3-319-69909-7_3823-2

15.

Dole

V. P.

Nyswander

(1965). A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride. JAMA, 193(8), 646–650. https://doi.org/10.1001/jama.1965.03090080008002

16.

Dole

V. P.

Nyswander

M. E.

(1967). Heroin addiction—A metabolic disease. Archives of Internal Medicine, 120(1), 19–24. https://doi.org/10.1001/archinte.1967.00300010021004

17.

Dole

V. P.

Nyswander

M. E.

Kreek

M. J.

(1966). Narcotic blockade. Archives of Internal Medicine, 118(4), 304–309. https://doi.org/10.1001/archinte.1966.00290160004002

18.

Duke

Thom

(2014). The role of evidence and the expert in contemporary processes of governance: The case of opioid substitution treatment policy in England. International Journal of Drug Policy, 25(5), 964–971. https://doi.org/10.1016/j.drugpo.2014.01.015

19.

Earnshaw

Smith

Copenhaver

(2013). Drug addiction stigma in the context of methadone maintenance therapy: An investigation into understudied sources of stigma. International Journal of Mental Health and Addiction, 11(1), 110–122. https://doi.org/10.1007/s11469-012-9402-5

20.

Engel

G. L.

(1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460

21.

Favril

Vander Laenen

Decorte

(2015). Schadebeperkende maatregelen voor de stad Gent. Een onderzoek naar de lokale noden en prioriteiten [Harm reduction measures for the city of Ghent. A study into local needs and priorities]. Maklu.

22.

Fiellin

D. A.

Schottenfeld

R. S.

Cutter

C. J.

Moore

B. A.

Barry

D. T.

O’Connor

P. G.

(2014). Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. JAMA Internal Medicine, 174(12), 1947–1954. https://doi.org/10.1001/jamainternmed.2014.5302

23.

Frank

L. E.

Nagel

S. K.

(2017). Addiction and moralization: The role of the underlying model of addiction. Neuroethics, 10(1), 129–139. https://doi.org/10.1007/s12152-017-9307-x

24.

Fraser

Valentine

(2008). Treatment identities. In Fraser

Valentine

(Eds.), Substance and substitution: Methadone subjects in liberal societies (pp. 113–141). Palgrave Macmillan. https://doi.org/10.1057/9780230582569_5

25.

Green

J. L.

Brock

Baker

W. D.

Harris

(2020). Positioning theory and discourse analysis: An explanatory theory and analytic lens. In Nasir

N. S.

Lee

C. D.

Pea

McKinney de Royston

(Eds.) Handbook of the cultural foundations of learning (pp. 119–140). Routledge.

26.

Guillain

(2017). Belgian drug policy. In Colson

Bergeron

(Eds.), European drug policies: The ways of reform (pp. 59–72). Routledge.

27.

Harré

Van Langenhove

(1999). Positioning theory: Moral contexts of intentional action. Blackwell. https://lib.ugent.be/catalog/rug01:000440441

28.

Harris

McElrath

(2012). Methadone as social control: Institutionalized stigma and the prospect of recovery. Qualitative Health Research, 22(6), 810–824. https://doi.org/10.1177/1049732311432718

29.

Henderson

N. L.

Dressler

W. W.

(2017). Medical disease or moral defect? Stigma attribution and cultural models of addiction causality in a university population. Culture, Medicine, and Psychiatry, 41(4), 480–498. https://doi.org/10.1007/s11013-017-9531-1

30.

Jakobsen

J. S.

Kloster

M. L.

Christensen

Johansen

K. S.

Kappel

Kronbæk

Fahnøe

K. R.

Houborg

(2022). Trade-offs in substitution treatment: A qualitative study of an opioid substitution therapy clinic as an enabling and a risk-environment. Contemporary Drug Problems, 49(1), 64–83. https://doi.org/10.1177/00914509211058988

31.

Jellinek . (2021). Welke opvattingen zijn er over verslaving? [What views are there about addiction?] https://www.jellinek.nl/vraag-antwoord/welke-opvattingen-zijn-er-over-verslaving/

32.

Justitie

F. O.

(2024). Drugs programma’s voor gedetineerden [Drug programs for detainees]. Federale Overheidsdienst Justitie.

33.

Kayi-Aydar

(2019). Positioning theory in applied linguistics: Research design & applications. Palgrave Macmillan.

34.

Keane

(2009). Foucault on methadone: Beyond biopower. International Journal of Drug Policy, 20(5), 450–452. https://doi.org/10.1016/j.drugpo.2008.10.005

35.

Kenworthy

Wright

Brown

Maria Madrigal

Dunlop

W. C. N.

(2017). Use of opioid substitution therapies in the treatment of opioid use disorder: Results of a UK cost-effectiveness modelling study. Journal of Medical Economics, 20(7), 740–748. https://doi.org/10.1080/13696998.2017.1325744

36.

Khantzian

E. J.

(2012). Reflections on treating addictive disorders: A psychodynamic perspective. The American Journal on Addictions, 21(3), 274–279. https://doi.org/10.1111/j.1521-0391.2012.00234.x

37.

Lassiter

P. S.

Spivey

M. S.

(2018). Historical perspectives and the moral model. In Lassiter

P. S.

Culbreth

J. R.

(Eds.), Theory and practice of addiction counseling (pp. 27–46). Sage.

38.

P.-P.

Braunack-Mayer

(2019). Perspectives on privacy in the pharmacy: The views of opioid substitution treatment clients. Research in Social and Administrative Pharmacy, 15(8), 1021–1026. https://doi.org/10.1016/j.sapharm.2019.02.003

39.

Liebschutz

J. M.

Crooks

Herman

Anderson

Tsui

Meshesha

L. Z.

Dossabhoy

Stein

(2014). Buprenorphine treatment for hospitalized, opioid-dependent patients: A randomized clinical trial. JAMA Internal Medicine, 174(8), 1369–1376. https://doi.org/10.1001/jamainternmed.2014.2556

40.

Link

B. G.

Phelan

J. C.

(2001). Conceptualizing stigma. Annual Review of Sociology, 27(1), 363–385. https://doi.org/10.1146/annurev.soc.27.1.363

41.

MacKillop

Ray

L. A.

(2017). The etiology of addiction: A contemporary biopsychosocial approach. In MacKillop

Kenna

G. A.

Leggio

Ray

L. A.

(Eds.), Integrating psychological and pharmacological treatments for addictive disorders: An evidence-based guide (pp. 32–53). Routledge.

42.

MacNeill

Brunelle

Skelding

DiTommaso

(2021). Experiences of clients in three types of methadone maintenance therapy in an Atlantic Canadian city: A qualitative study. Canadian Journal of Nursing Research, 53(3), 211–221. https://doi.org/10.1177/0844562120924516

43.

Madden

E. F.

(2019). Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Social Science & Medicine, 232, 324–331. https://doi.org/10.1016/j.socscimed.2019.05.027

44.

Mayock

Butler

(2022). “I’m always hiding and ducking and diving”: The stigma of growing older on methadone. Drugs: Education, Prevention and Policy, 29(2), 139–149. https://doi.org/10.1080/09687637.2021.1886253

45.

McCradden

M. D.

Vasileva

Orchanian-Cheff

Buchman

D. Z.

(2019). Ambiguous identities of drugs and people: A scoping review of opioid-related stigma. International Journal of Drug Policy, 74, 205–215. https://doi.org/10.1016/j.drugpo.2019.10.005

46.

Nyashanu

Scheibe

Visser

(2024). ‘I went for rehab many times and it never worked, but the harm reduction process has given me renewed hope’. Perceptions on the effectiveness of harm reduction and community-based opioid substitution therapy. Health Promotion Journal of Australia, 35(3), 653–661. https://doi.org/10.1002/hpja.789

47.

O’Byrne

Jeske Pearson

(2019). Methadone maintenance treatment as social control: Analyzing patient experiences. Nursing Inquiry, 26(2), Article e12275. https://doi.org/10.1111/nin.12275

48.

Patil Vishwanath

Cash

Cant

Mummery

Penney

(2019). The lived experience of Australian opioid replacement therapy recipients in a community‐based program in regional Victoria. Drug and Alcohol Review, 38(6), 656–663. https://doi.org/10.1111/dar.12979

49.

Pelz

Overstreet

(2022). Developmental psychology. NSCC.

50.

Platt

Minozzi

Reed

Vickerman

Hagan

French

Jordan

Degenhardt

Hope

Hutchinson

Maher

Palmateer

Taylor

Bruneau

Hickman

(2018). Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: Findings from a Cochrane review and meta-analysis. Addiction, 113(3), 545–563. https://doi.org/10.1111/add.14012

51.

Radley

Melville

Easton

Williams

Dillon

J. F.

(2017). ‘Standing Outside the Junkie Door’—Service users’ experiences of using community pharmacies to access treatment for opioid dependency. Journal of Public Health, 39(4), 846–855. https://doi.org/10.1093/pubmed/fdw138

52.

Richard

E. L.

Schalkoff

C. A.

Piscalko

H. M.

Brook

D. L.

Sibley

A. L.

Lancaster

K. E.

Miller

W. C.

V. F.

(2020). “You are not clean until you’re not on anything”: Perceptions of medication-assisted treatment in rural Appalachia. International Journal of Drug Policy, 85(4), Article 102704. https://doi.org/10.1016/j.drugpo.2020.102704

53.

Roberts

(2023). The biopsychosocial model: Its use and abuse. Medicine, Healthcare & Philosophy, 26(3), 367–384. https://doi.org/10.1007/s11019-023-10150-2

54.

Rødner

(2005). “I am not a drug abuser, I am a drug user”: A discourse analysis of 44 drug users’ construction of identity. Addiction Research & Theory, 13(4), 333–346. https://doi.org/10.1080/16066350500136276

55.

Rozanova

Marcus

Taxman

F. S.

Bojko

M. J.

Madden

Farnum

S. O.

Mazhnaya

Dvoriak

Altice

F. L.

(2017). Why people who inject drugs voluntarily transition off methadone in Ukraine. Qualitative Health Research, 27(13), 2057–2070. https://doi.org/10.1177/1049732317732307

56.

Scorsone

K. L.

Haozous

E. A.

Hayes

Cox

K. J.

(2020). Overcoming barriers: Individual experiences obtaining medication-assisted treatment for opioid use disorder. Qualitative Health Research, 30(13), 2103–2117. https://doi.org/10.1177/1049732320938689

57.

Scott

Murphy

C. M.

Yap

Moul

Hurley

Becker

S. J.

(2021). Health professional stigma as a barrier to contingency management implementation in opioid treatment programs. Translational Issues in Psychological Science, 7(2), 166–176. https://doi.org/10.1037/tps0000245

58.

Selbekk

A. S.

Adams

P. J.

Sagvaag

(2018). “A problem like this is not owned by an individual”: Affected family members negotiating positions in alcohol and other drug treatment. Contemporary Drug Problems, 45(2), 146–162. https://doi.org/10.1177/0091450918773097

59.

Sibley

A. L.

Schalkoff

C. A.

Richard

E. L.

Piscalko

H. M.

Brook

D. L.

Lancaster

K. E.

Miller

W. C.

V. F.

(2020). “I was raised in addiction”: Constructions of the self and the other in discourses of addiction and recovery. Qualitative Health Research, 30(14), 2278–2290. https://doi.org/10.1177/1049732320948829

60.

Skewes

Gonzalez

(2013). The biopsychosocial model of addiction. In Miller

P. M.

Blume

A. W.

Kavanagh

D. J.

Kampman

K. M.

Bates

M. E.

Larimer

M. E.

Petry

N. M.

De Witte

Ball

S. A.

(Eds.), Principles of addiction: Comprehensive addictive behaviors and disorders (Vol. 1, pp. 61–70). Academic Press. https://doi.org/10.1016/B978-0-12-398336-7.00006-1

61.

Sordo

Barrio

Bravo

M. J.

Indave

B. I.

Degenhardt

Wiessing

Ferri

Pastor-Barriuso

(2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357, Article j1550. https://doi.org/10.1136/bmj.j1550

62.

Strada

Schmidt

C. S.

Rosenkranz

Verthein

Scherbaum

Reimer

Schulte

(2019). Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: A cross-sectional study. Substance Abuse Treatment, Prevention, and Policy, 14(1), Article 2. https://doi.org/10.1186/s13011-018-0187-9

63.

Sud

Strang

Buchman

D. Z.

Spithoff

Upshur

R. E. G.

Webster

Grundy

(2022). How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: A critical discourse analysis. BMJ Open, 12(7), Article e059561. https://doi.org/10.1136/bmjopen-2021-059561

64.

Uhl

G. R.

Koob

G. F.

Cable

(2019). The neurobiology of addiction. Annals of the New York Academy of Sciences, 1451(1), 5–28. https://doi.org/10.1111/nyas.13989

65.

VAD . (2024). Wat is Subutex (buprenorfine)? De Druglijn. https://www.druglijn.be/drugs/methadon/wat-is-subutex-buprenorfine/

66.

Van den Bogaert

Ceuterick

Bracke

(2020). The silver lining of greying: Ageing discourses and positioning of ageing persons in the field of social health insurance. Health, 24(2), 169–186. https://doi.org/10.1177/1363459318800171

67.

Vander Laenen

Vanderplasschen

Smet

(2013). Analysis and optimization of substitution treatment in Belgium. Academia Press.

68.

van der Stel

(2013). Niks geen hersenziekte [Nothing like a brain disease]. Verslaving, 9(4), 31–33. https://doi.org/10.1007/s12501-013-0034-7

69.

Van Langenhove

(2022). Positioning theory. In Glǎveanu

V. P.

(Ed.), The Palgrave encyclopedia of the possible. Palgrave Macmillan.

70.

Woo

Bhalerao

Bawor

Bhatt

Dennis

Mouravska

Zielinski

Samaan

(2017). “Don’t judge a book its cover”: A qualitative study of methadone patients’ experiences of stigma. Substance Abuse: Research and Treatment, 11. https://doi.org/10.1177/1178221816685087

71.

Wood

L. A.

Kroger

R. O.

(2000). Doing discourse analysis: Methods for studying action in talk and text. Sage.

72.

(2023). Parallel development: Medicalization and decriminalization in the changing media framing of the opioid overdose crisis. Socius, 9(5), 1–16. https://doi.org/10.1177/23780231231186731

73.

Zestcott

C. A.

Blair

I. V.

Stone

(2016). Examining the presence, consequences, and reduction of implicit bias in health care: A narrative review. Group Processes & Intergroup Relations, 19(4), 528–542. https://doi.org/10.1177/1368430216642029

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.07 MB